Ursodeoxycholic acid (Ursofalk®)

All Wales Medicines Strategy Group (AWMSG)
Record ID 32016000671
Authors' recommendations: Ursodeoxycholic acid (Ursofalk®) is recommended for use within NHS Wales for the treatment of hepatobiliary disorders associated with cystic fibrosis in children aged 1 month to 18 years.
Project Status: Completed
Year Published: 2016
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
MeSH Terms
  • Humans
  • Cholagogues and Choleretics
  • Liver Cirrhosis, Biliary
  • Ursodeoxycholic Acid
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name: AWTTC@wales.nhs.uk
Contact Email: AWTTC@wales.nhs.uk
Copyright: AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.